Search Page

1

Cite

Share

The development of a comprehensive risk-management program for prescription opioid analgesics: researched abuse, diversion and addiction-related surveillance (RADARS).

Cicero TJ, Dart RC, Inciardi JA, Woody GE, Schnoll S, Muñoz A. Cicero TJ, et al. Among authors: schnoll s. Pain Med. 2007 Mar;8(2):157-70. doi: 10.1111/j.1526-4637.2006.00259.x. Pain Med. 2007. PMID: 17305687

Cite

Share

2

Cite

Share

A postmarketing surveillance program to monitor Ultram (tramadol hydrochloride) abuse in the United States.

Cicero TJ, Adams EH, Geller A, Inciardi JA, Muñoz A, Schnoll SH, Senay EC, Woody GE. Cicero TJ, et al. Among authors: schnoll sh. Drug Alcohol Depend. 1999 Nov 1;57(1):7-22. doi: 10.1016/s0376-8716(99)00041-1. Drug Alcohol Depend. 1999. PMID: 10617309

Cite

Share

3

Cite

Share

Real-world misuse, abuse, and dependence of abuse-deterrent versus non-abuse-deterrent extended-release morphine in Medicaid non-cancer patients.

Cicero TJ, Mendoza M, Cattaneo M, Dart RC, Mardekian J, Polson M, Roland CL, Schnoll SH, Webster LR, Park PW. Cicero TJ, et al. Among authors: schnoll sh. Postgrad Med. 2019 Apr;131(3):225-229. doi: 10.1080/00325481.2019.1585688. Epub 2019 Mar 19. Postgrad Med. 2019. PMID: 30794760

Cite

Share

4

Cite

Share

Do abuse deterrent opioid formulations work?

Dart RC, Iwanicki JL, Dasgupta N, Cicero TJ, Schnoll SH. Dart RC, et al. J Opioid Manag. 2017 Nov/Dec;13(6):365-378. doi: 10.5055/jom.2017.0415. J Opioid Manag. 2017. PMID: 29308584 Review.

Cite

Share

5

Cite

Share

Misconceptions and Realities of the Prescription Opioid Epidemic.

Schnoll SH. Schnoll SH. Clin Pharmacol Ther. 2018 Jun;103(6):963-965. doi: 10.1002/cpt.1033. Epub 2018 Feb 21. Clin Pharmacol Ther. 2018. PMID: 29464692

Cite

Share

6

Cite

Share

Opioid treatment of chronic pain in patients with addiction.

Weaver MF, Schnoll SH. Weaver MF, et al. J Pain Palliat Care Pharmacother. 2002;16(3):5-26. doi: 10.1080/j354v16n03_02. J Pain Palliat Care Pharmacother. 2002. PMID: 14640352 Review.

Cite

Share

7

Cite

Share

Challenges in the development of prescription opioid abuse-deterrent formulations.

Katz NP, Adams EH, Chilcoat H, Colucci RD, Comer SD, Goliber P, Grudzinskas C, Jasinski D, Lande SD, Passik SD, Schnoll SH, Sellers E, Travers D, Weiss R. Katz NP, et al. Clin J Pain. 2007 Oct;23(8):648-60. doi: 10.1097/AJP.0b013e318125c5e8. Clin J Pain. 2007. PMID: 17885342 Review.

Cite

Share

8

Cite

Share

An analysis of the root causes for opioid-related overdose deaths in the United States.

Webster LR, Cochella S, Dasgupta N, Fakata KL, Fine PG, Fishman SM, Grey T, Johnson EM, Lee LK, Passik SD, Peppin J, Porucznik CA, Ray A, Schnoll SH, Stieg RL, Wakeland W. Webster LR, et al. Among authors: schnoll sh. Pain Med. 2011 Jun;12 Suppl 2:S26-35. doi: 10.1111/j.1526-4637.2011.01134.x. Pain Med. 2011. PMID: 21668754

Cite

Share

9

Cite

Share

Prescription opioid abuse among enrollees into methadone maintenance treatment.

Rosenblum A, Parrino M, Schnoll SH, Fong C, Maxwell C, Cleland CM, Magura S, Haddox JD. Rosenblum A, et al. Among authors: schnoll sh. Drug Alcohol Depend. 2007 Sep 6;90(1):64-71. doi: 10.1016/j.drugalcdep.2007.02.012. Epub 2007 Mar 26. Drug Alcohol Depend. 2007. PMID: 17386981

Cite

Share

10

Cite

Share

Tramadol post-marketing surveillance in health care professionals.

Knisely JS, Campbell ED, Dawson KS, Schnoll SH. Knisely JS, et al. Among authors: schnoll sh. Drug Alcohol Depend. 2002 Sep 1;68(1):15-22. doi: 10.1016/s0376-8716(02)00107-2. Drug Alcohol Depend. 2002. PMID: 12167549 Clinical Trial.

Cite

Share